Log in

NASDAQ:ITMN - InterMune Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
InterMune, Inc (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:ITMN
CUSIP45884X10
WebN/A
Phone+1-415-4662200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ITMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ITMN and its competitors with MarketBeat's FREE daily newsletter.


InterMune (NASDAQ:ITMN) Frequently Asked Questions

What is InterMune's stock symbol?

InterMune trades on the NASDAQ under the ticker symbol "ITMN."

Has InterMune been receiving favorable news coverage?

Media coverage about ITMN stock has been trending very negative on Sunday, InfoTrie reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. InterMune earned a news sentiment score of -3.6 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for InterMune.

Who are some of InterMune's key competitors?

What other stocks do shareholders of InterMune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InterMune investors own include Agios Pharmaceuticals (AGIO), Booking (BKNG), Alphabet (GOOG), Intercept Pharmaceuticals (ICPT), Align Technology (ALGN), Celgene (CELG), Gilead Sciences (GILD), Illumina (ILMN), Medivation (MDVN) and Netflix (NFLX).

How can I contact InterMune?

InterMune's mailing address is 3280 Bayshore Blvd, BRISBANE, CA 94005-1021, United States. The biotechnology company can be reached via phone at +1-415-4662200.


MarketBeat Community Rating for InterMune (NASDAQ ITMN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  217 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about InterMune and other stocks. Vote "Outperform" if you believe ITMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel